


JFW

Please Direct All Correspondence to Customer Number **20995****TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT**


Applicant : Sallberg et al.
App. No : 10/817,591
Filed : April 2, 2004
For : VACCINES CONTAINING RIBAVIRIN
AND METHODS OF USE THEREOF
Examiner : Bao Q. Li
Art Unit : 1648

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 13, 2005

(Date)


Eric S. Furman, Ph.D., Reg. No. 45,664**Mail Stop Amendment**

Commissioner for Patents


P.O. Box 1450


Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
- (X) Listing twenty nine (29) references.
 - (X) Enclosing twenty (20) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant : Sallberg et al
App. No : 10/817,591
Filed : April 2, 2004
For : VACCINES CONTAINING
RIBAVIRIN AND METHODS OF USE
THEREOF
Examiner : Bao Q. Li
Art Unit : 1648

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed is a PTO/SB/08 Equivalent listing 29 references. References numbered 1-9 are of record in U.S. patent application No. 09/929955, filed August 15, 2001, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Accordingly, copies of references numbered 1-9 are not submitted pursuant to 37 C.F.R. § 1.98(d). Copies of references 10-29 are enclosed with this paper.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Sept. 13, 2005

By: 
Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	10/817,591
Filing Date	April 2, 2004
First Named Inventor	Sallberg et al
Art Unit	1648
Examiner	Bao Q. Li
Attorney Docket No.	TRIPEP.23AUS2C1

(Multiple sheets used when necessary)

SHEET 1 OF 2

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5,766,845	6/1/1998	Weiner et al.	
	2	5,847,101	12/1/1998	Okayama et al	
	3	5,879,904	3/1/1999	Brechot et al.	
	4	6,153,421	11/1/2000	Yanagi et al.	
	5	6,653,125	11/25/2003	Donnelly et al.	
	6	08/008,342	1/26/1993	Weiner et al	
	7	08/029,336	3/11/1993	Weiner et al.	
	8	08/125,012	9/21/1993	Weiner et al.	
	9	08/221,579	4/1/1994	Carrano et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	10	WO 01/38360	5/31/2001	Chiron Corporation		
	11	WO 01/96875	12/20/2001	Chiron Corporation		
	12	WO 03/031588	4/17/2003	Merck & Co., INC.,		
	13	WO 98/37180	8/27/1998	Abbott Laboratories		
	14	WO 96/09805	4/4/1996	Zonagen, INC.		
	15	WO 96/33739	10/31/1996	Smithline Beecham Biologicals S.A.		
	16	WO 97/47358	12/18/1997	Merck & Co., INC.,		
	17	WO 98/34640	8/13/1998	Merck & Co., INC.,		
	18	WO 99/04008	1/28/1999	The Dept. of Health and Human Services		
	19	WO 99/28482	6/10/1999	Schering Corporation		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	20	ANDRE et al., "Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp120 Sequence with Optimized Codon Usage," Journal of Virology, 72(2):1497-1503(1998).	

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/817,591
	Filing Date	April 2, 2004
	First Named Inventor	Sallberg et al
	Art Unit	1648
(Multiple sheets used when necessary)	Examiner	Bao Q. Li
SHEET 2 OF 2	Attorney Docket No.	TRIPEP.23AUS2C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	21	DATABASE GENBANK [Online] 12/02/94, retrieved from NCBI Database accession no.I06434, XP002278035.	
	22	DATABASE REGISTRY [Online] No. 511600-20-7, XP02278058 abstract & WO 03/031588A, 04/17/03, Seq ID No.1, 10 and 11 Claims	
	23	ENCKE et al., "DNA Vaccines," Intervirology, 42:117-124, (1999).	
	24	FORNS et al., "Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resalving or persistent infection in chimpanzees," PNAS, vol. 97, No. 24, pp. 13318-113323, (2000).	
	25	HAHM et al., "NS3-4A of Hepatitis C Virus is a Chymotrypsin-Like Protease," Journal of Virology, The American Society for Microbiology, 69(4): 2534-2539 (1995).	
	26	KUMAR et al., "Hepatitis C virus genomic RNA for polyprotein gene," Journal of Hepatology, 7:459-465 (2000).	
	27	LAZDINA et al., "Humoral and CD4* T helper (th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes TH 1-like responses more effectively as a DNA-Based immunogen than as a recombinant protein," Journal of General Virology, 82:1299-1308 (2001).	
	28	LOHMANN et al., "Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line," Science, 285:110-113, (1999).	
	29	NCBI, Genbank, M32084. Hepatitis C Virus. . . [Gi:32987] August 02, 1993	

1914152:MRF
090605

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.